Announcements Trials
Browse Landscape

Phase

Phase 1 19Phase 2 12Phase 1/2 9Phase EARLY_PHASE1 4Phase 3 4Phase NA 1

Status

Suspended 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Classical hematology 1

Conditions

Colorectal Neoplasms 8Glioma 7Breast Neoplasms 7Neoplasms 6Glioblastoma 6Pancreatic Neoplasms 5Neoplasm Metastasis 5Recurrence 4Lymphoma, B-Cell 4Lymphoma 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Multiple Myeloma 3Melanoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pancreatic Ductal Adenocarcinoma 2Myelodysplastic Syndromes 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1

Interventions

venetoclax 1tafasitamab 1glofitamab 1Rituximab 1Gemcitabine 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma, B-Cell × 30 days × Clear all
NCT07205315 2026-05-27

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Grit Biotechnology

Phase EARLY_PHASE1 Recruiting
28 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07584850 2026-05-13

Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Ruijin Hospital

Phase EARLY_PHASE1 Not yet recruiting
9 enrolled
Lymphoid

Lymphoma, B-Cell

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

NCT06662227 2026-05-07

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

Wondercel Biotech (ShenZhen)

Phase EARLY_PHASE1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡